Long lasting facial rejuvenation by repeated placement of calcium hydroxylapatite in elderly women.


Journal

Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070

Informations de publication

Date de publication:
11 2020
Historique:
received: 10 07 2020
revised: 20 07 2020
accepted: 07 08 2020
pubmed: 15 8 2020
medline: 15 5 2021
entrez: 15 8 2020
Statut: ppublish

Résumé

Calcium hydroxylapatite (CaHA) is a biostimulatory filler with long lasting efficacy after a single injection. Data con the effect of repeated injections, however, are sparse. This is a single-center observational study. Forty Caucasian females of Fitzpatrick skin type I to III, aged between 50 and 95 years (mean age 63 ± 13.4 years), and seeking nonsurgical improvement of facial aging were included. Patients with previous face lifts, threads or other surgical treatments were excluded. Only women ≥50 years of age were included. Midface and lower face were treated, that is, cheeks, tear troughs, jawline, and Marionette lines. The usual time for a repetition of filler injection was 12 to 14 months. Mean follow-up was 36 ± 10.8 months after first injection of Radiesse. Outcome was measured using the Global Aesthetic Improvement Scale (GAIS). Mean patient's GAIS was 2.7 ± 0.7, while physicians GAIS was 2.6 ± 0.6 suggesting a remarkable improvement 12 months after the first procedure. Mean patient's GAIS at 3 and 5 years after first procedure was 2.4 ± 0.8, while physicians GAIS was 2.5 ± 0.7. Repeated injection of CaHA leads to a significant and long-lasting improvement of facial appearance.

Identifiants

pubmed: 32794331
doi: 10.1111/dth.14183
doi:

Substances chimiques

Durapatite 91D9GV0Z28
Calcium SY7Q814VUP

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14183

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Misiek DJ, Kent JN, Carr RF. Soft tissue responses to hydroxylapatite particles of different shapes. J Oral Maxillofac Surg. 1984;42(3):150-160.
Drobeck HP, Rothstein SS, Gumaer KI, Sherer AD, Slighter RG. Histologic observation of soft tissue responses to implanted, multifaceted particles and discs of hydroxylapatite. J Oral Maxillofac Surg. 1984;42(3):143-149.
Pettis GY, Kaban LB, Glowacki J. Tissue response to composite ceramic hydroxyapatite/demineralized bone implants. J Oral Maxillofac Surg. 1990;48(10):1068-1074.
Hobar PC, Pantaloni M, Byrd HS. Porous hydroxyapatite granules for alloplastic enhancement of the facial region. Clin Plast Surg. 2000;27(4):557-569.
Havlik RJ, PSEF DATA Committee. Hydroxyapatite. Plast Reconstr Surg. 2002;110(4):1176-1179.
Wollina U, Wiegand C, Hipler UC. Calcium hydroxylapatite microspheres - biocompatibility and clinical effects. Georgian Med News. 2018;278:62-68.
Rosamilia G, Hamade H, Freytag DL, et al. Soft tissue distribution pattern of facial soft tissue fillers with different viscoelastic properties. J Cosmet Dermatol. 2020;19(2):312-320.
Sundaram H, Cassuto D. Biophysical characteristics of hyaluronic acid soft-tissue fillers and their relevance to aesthetic applications [published correction appears in Plast Reconstr Surg. 2013 Nov;132(5):1378]. Plast Reconstr Surg. 2013;132(4 Suppl 2):5S-21S.
Pavicic T. Complete biodegradable nature of calcium hydroxylapatite after injection for malar enhancement: an MRI study. Clin Cosmet Invest Dermatol. 2015;8:19-25.
Coleman KM, Voigts R, DeVore DP, et al. Neocollagenesis after injection of calcium hydroxylapatite composition in a canine model. Dermatol Surg. 2008;34(suppl 1):S53-S55.
Berlin AL, Hussain M, Goldberg DJ. Calcium hydroxylapatite filler for facial rejuvenation: a histologic and immunohistochemical analysis. Dermatol Surg. 2008;34(Suppl 1):S64-S67.
Marmur ES, Phelps R, Goldberg DJ. Clinical, histologic and electron microscopic findings after injection of a calcium hydroxylapatite filler. J Cosmet Laser Ther. 2004;6(4):223-226.
Yutskovskaya YA, Kogan EA. Improved neocollagenesis and skin mechanical properties after injection of diluted calcium hydroxylapatite in the neck and décolletage: a pilot study. J Drugs Dermatol. 2017;16:68-74.
Yutskovskaya Y, Kogan E, Leshunov E. A randomized, split-face, histomorphologic study comparing a volumetric calcium hydroxylapatite and a hyaluronic acid-based dermal filler. J Drugs Dermatol. 2014;13:47-52.
Zerbinati N, Calligaro A. Calcium hydroxylapatite treatment of human skin: evidence of collagen turnover through picrosirius red staining and circularly polarized microscopy. Clin Cosmet Invest Dermatol. 2018;11:29-35.
Kadouch JA. Calcium hydroxylapatite: a review on safety and complications. J Cosmet Dermatol. 2017;16(2):152-161.
Wollina U. Improvement of tear trough by monophasic hyaluronic acid and calcium hydroxylapatite. J Clin Aesthet Dermatol. 2014;7(10):38-43.
Wollina U. Facial rejuvenation starts in the midface: three-dimensional volumetric facial rejuvenation has beneficial effects on nontreated neighboring esthetic units. J Cosmet Dermatol. 2016;15(1):82-88.
Wollina U, Goldman A. Minimal invasive chin and jawline improvement in women in the second half of their life. Dermatol Ther. 2020;33(3):e13320.
Hersant B, Abbou R, SidAhmed-Mezi M, Meningaud JP. Assessment tools for facial rejuvenation treatment: a review. Aesthetic Plast Surg. 2016;40(4):556-565.
Muti GF. Open-label, post-marketing study to evaluate the performance and safety of calcium Hydroxylapatite with integral lidocaine to correct facial volume loss. J Drugs Dermatol. 2019;18(1):86-91.
Lorenc ZP, Bass LM, Fitzgerald R, Goldberg DJ, Graivier MH. Composite facial Volumization with calcium Hydroxylapatite (CaHA) for the treatment of aging. Aesthet Surg J. 2018;38(suppl 1):S18-S23.
Simunovic F, Schlager S, Montanari M, Iblher N. Prospective 3D analysis of facial soft tissue augmentation with calcium hydroxylapatite. J Cosmet Laser Ther. 2017;19(5):283-289.
Tzikas TL. Evaluation of the radiance FN soft tissue filler for facial soft tissue augmentation. Arch Facial Plast Surg. 2004;6(4):234-239.
Jacovella PF, Peiretti CB, Cunille D, Salzamendi M, Schechtel SA. Long-lasting results with hydroxylapatite (Radiesse) facial filler. Plast Reconstr Surg. 2006;118(3 Suppl):15S-21S.
Moers-Carpi M, Storck R, Howell DJ, Ogilvie P, Ogilvie A. Physician and patient satisfaction after use of calcium hydroxylapatite for cheek augmentation. Dermatol Surg. 2012;38(7 Pt 2):1217-1222.
Bass LS, Smith S, Busso M, McClaren M. Calcium hydroxylapatite (Radiesse) for treatment of nasolabial folds: long-term safety and efficacy results. Aesthet Surg J. 2010;30(2):235-238.
Fakhre GP, Perdikis G, Shaddix KK, Terkonda SP, Waldorf JC. An evaluation of calcium hydroxylapatite (Radiesse) for cosmetic nasolabial fold correction: a meta-analysis and patient centric outcomes study. Ann Plast Surg. 2009;63(5):486-489.
Jansen DA, Graivier MH. Evaluation of a calcium hydroxylapatite-based implant (Radiesse) for facial soft-tissue augmentation. Plast Reconstr Surg. 2006;118(3 Suppl):22S-33S.
Wollina U. Midfacial rejuvenation by hyaluronic acid fillers and subcutaneous adipose tissue - a new concept. Med Hypotheses. 2015;84(4):327-330.
Kruglikov IL, Wollina U. Soft tissue fillers as non-specific modulators of adipogenesis: change of the paradigm? Exp Dermatol. 2015;24(12):912-915.
Wollina U, Wetzker R, Abdel-Naser MB, Kruglikov IL. Role of adipose tissue in facial aging. Clin Interv Aging. 2017;12:2069-2076.
Yoo G, Lim JS. Tissue engineering of injectable soft tissue filler: using adipose stem cells and micronized acellular dermal matrix. J Korean Med Sci. 2009;24(1):104-109.
Nowacki M, Pietkun K, Pokrywczyńska M, et al. Filling effects, persistence, and safety of dermal fillers formulated with stem cells in an animal model. Aesthet Surg J. 2014;34(8):1261-1269.

Auteurs

Uwe Wollina (U)

Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Dresden, Germany.

Alberto Goldman (A)

Department of Plastic Surgery, Clinica Goldman, Porto Alegre, Rio Grande do Sul, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH